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Summary
 
In this paper, we test the hypothesis that triggering of a second T cell receptor (TCR) ex-
pressed on diabetogenic T cells might initiate the onset of diabetes. A cross between two
TCR-transgenic strains, the BDC2.5 strain that carries diabetogenic TCRs and the A18 strain
that carries receptors specific for C5, was set up to monitor development of diabetes after acti-
vation through the C5 TCR. F1 BDC2.5 
 
3
 
 A18 mice developed diabetes spontaneously be-
yond 3–4 mo of age. Although their T cells express both TCRs constitutively, the A18 recep-
tor is expressed at extremely low levels. In vitro activation of dual TCR T cells followed by
adoptive transfer into neonatal or adult F1 mice resulted in diabetes onset and death within 10 d
after transfer. In contrast, in vivo immunization of F1 mice with different forms of C5 antigen
not only failed to induce diabetes but protected mice from the spontaneous onset of diabetes.
We propose that antigenic stimulation of cells with low levels of TCR produces signals inade-
quate for full activation, resulting instead in anergy.
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T
 
he existence of T cells with two TCR-
 
a
 
 chains is a
consequence of gene rearrangement at the 
 
a
 
 chain lo-
cus, which only terminates once an 
 
a/b
 
 TCR is expressed
that allows positive selection of the cell (1). Therefore, T
cells expressing two TCRs composed of the same 
 
b
 
 chain
paired with two different 
 
a
 
 chains are not infrequent (2–4).
We have previously shown that expression of a second re-
ceptor in a transgenic model can rescue T cells with recep-
tors for self-antigen from thymic deletion, provided that
these are expressed at low levels (5, 6). Such rescued cells
could not be activated through their self-antigen–specific
receptors, but once activated via the second TCR, they
were capable of autoreactive effector function in vitro. This
posed the question of whether dual receptor–expressing T
cells might be able to initiate autoimmune disease. To test
such a hypothesis in vivo, we made use of an experimental
diabetes model. The BDC2.5 TCR-transgenic mouse
strain expresses diabetogenic TCRs on a NOD background
(7). These mice have been shown to spontaneously de-
velop diabetes, albeit with late onset, irrespective of the
presence of other MHC molecules, e.g., H-2E, which in
nontransgenic NOD mice prevent diabetes (8). It is not
known what triggers the onset of islet destruction, but the
presence of a second TCR is not essential, as BDC2.5 mice
on a SCID background develop diabetes even earlier than
transgenic mice with a diverse repertoire (9). Animal mod-
els of autoimmune diseases provide evidence that additional
contributing factors, e.g., viral or bacterial infections, play
an ill-defined role in triggering the disease in genetically
susceptible animals (10–12). We crossed BDC2.5 trans-
genic mice with the A18 transgenic strain, which expresses
C5-specific TCRs (5), so that T cells in the F1 hybrid
would constitutively express both receptors. Immunization
of these mice with C5 served to test whether onset of diabetes
could be triggered via stimulation of the second TCR.
 
Materials and Methods
 
Transgenic Mice.
 
A18 TCR-transgenic Rag1
 
2
 
/
 
2
 
C5
 
2
 
/
 
2
 
 mice
on an A/J background (5) (TCR specific for epitope 106–121 of
mouse complement C5 presented by H2-E
 
k
 
) were crossed with
the BDC2.5 strain (7) recognizing an unidentified peptide from
islet cells presented with H-2A
 
g7
 
, which we received from Drs.
Diane Mathis and Christophe Benoist. These mice are Rag
 
1
 
/
 
1
 
C5
 
2
 
/
 
2
 
 and have been backcrossed onto a NOD background for
16 generations. Both parental strains were heterozygous for TCR
expression so that the resulting F1 mice expressed either the A18
receptor alone (F1 A18
 
1
 
), the BDC2.5 receptor alone (F1
BDC
 
1
 
), or both receptors (F1 dual TCR).
 
Flow Cytometry.
 
Lymph node cell suspensions were stained
with PE-conjugated anti-CD4 (PharMingen), FITC-conjugated
anti-V
 
b
 
8.3 (13) specific for the A18 TCR 
 
b
 
 chain, and biotiny- 
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lated anti-V
 
b
 
4 (PharMingen) specific for the BDC2.5 TCR 
 
b
 
chain, followed by streptavidin Red 670 (GIBCO BRL).
 
Cell Cultures.
 
Cells were stimulated in round-bottomed 96-
well plates (2 
 
3
 
 10
 
5
 
 cells/well) with dendritic cells from bone
marrow cultures with GM-CSF (2 
 
3
 
 10
 
4
 
/well). Culture medium
was IMDM (Sigma Chemical Co.) supplemented with 5% FCS,
5 
 
3
 
 10
 
2
 
5 
 
M 2-ME, 2 
 
3
 
 10
 
2
 
3 
 
M 
 
l
 
-glutamine, 100 U/ml penicil-
lin, and 100 
 
m
 
g/ml streptomycin. After culture for 48 h, aliquots
of supernatants were removed and tested for IL-2 content in se-
rial dilutions on IL-2–dependent CTLL cells. Bone marrow–
derived dendritic cells were generated as previously described
(14, 15) with some modifications (16). In brief, 5 
 
3
 
 10
 
6
 
 bone
marrow cells were cultured in petri dishes (9-cm diameter; Nunc,
Inc.) in 10 ml culture medium containing 10% supernatant of
Ag8653 myeloma cells transfected with murine GM-CSF cDNA
(
 
<
 
 
 
25 U/ml). On day 4 of culture, nonadherent cells, mostly
granulocytes, were removed. Loosely adherent cells were trans-
ferred onto a second dish on day 6 of culture. From day 6 to 10,
these transferred cells were used as a source of dendritic cells. Islet
antigen for stimulation of BDC2.5 was prepared by subcellular
fractionation of beta-tumor cells as previously described (17).
 
Transfer of In Vitro–activated Spleen Cells.
 
Spleen cells from
dual or single TCR–expressing F1 mice were depleted of B cells
with sheep anti–mouse IgG–coupled Dynabeads (Dynal, Inc.)
and cultured at 2 
 
3
 
 10
 
5
 
/ml with 2 
 
3
 
 10
 
4
 
/ml dendritic cells in
25-ml culture flasks (Falcon Labware). 48 h later, cells were col-
lected, washed, and injected intravenously into host mice.
 
Measurement of Cytokine Production in Cells from Pancreatic Drain-
ing Lymph Nodes.
 
Cell suspensions from pancreatic lymph
nodes (2 
 
3
 
 10
 
5
 
/well) were prepared by digestion with a cocktail
of 1.6 mg/ml Collagenase (Worthington CLS4) and 0.1% DNase
(Sigma Chemical Co.) for 30 min at 37
 
8
 
C. 2 
 
3
 
 10
 
5
 
 lymph node
cells per well were then cultured with different doses of C5 pro-
tein, and supernatants were removed after 48 h (for IL-2 and IL-10
measurements) or 72 h for measurement of IFN-
 
g
 
 production.
 
IL-2 production was determined by a bioassay with the IL-2–
dependent CTLL line, whereas IL-10 and IFN-
 
g
 
 production was
measured in a sandwich ELISA using pairs of antibodies for each
cytokine (PharMingen cytokine kits).
 
Measurement of Blood Glucose Levels.
 
Diabetes was assessed by
weekly measurements of venous blood glucose concentration us-
ing BM-Test 1-44 strips and Reflolux S glucometer (Boehringer
Mannheim). Animals were considered diabetic after at least two
consecutive measurements 
 
.
 
12 mM. Onset of diabetes was then
dated from the first of the sequential (glucose or diabetic) mea-
surements. After sustained hyperglycemia, mice were killed to
prevent prolonged discomfort.
 
Results
 
T Cells from BDC2.5 
 
3 
 
A18 F1 Mice Express Both TCRs.
 
The BDC2.5 TCR-transgenic strain recognizes an uniden-
tified peptide from islet cells presented by H-2A
 
g7
 
, whereas
the A18 TCR-transgenic strain recognizes a peptide from
the mouse complement component C5. Both strains are
C5
 
2
 
/
 
2
 
 and all mice are Rag
 
1
 
, as the BDC2.5 strain has not
been crossed onto a Rag
 
2
 
/
 
2
 
 background. BDC2.5 and A18
mice, heterozygous for expression of their transgenic
TCRs, were crossed to obtain F1 offspring transgenic for
the A18 TCR (F1 A18
 
1
 
), the BDC2.5 TCR (F1 BDC
 
1
 
),
or both (F1 dual TCR). T cells from all F1 mice were ana-
lyzed for expression of V
 
b
 
4 and V
 
b
 
8.3 (the BDC and A18
TCR-
 
b
 
 chains respectively). As shown in the Fig. 1 histo-
gram overlays gated for CD4 T cells, expression of the
BDC V
 
b
 
4 chain is only slightly lower in dual TCR F1
mice compared with F1 mice expressing the parental
BDC2.5 TCR alone, whereas expression of the A18
Figure 1. (A) Spleen cells were triple stained with anti-Vb8.3–FITC, anti-Vb4–biotin, and anti-CD4–PE. Expression of TCR b chains characteristic
for A18 (Vb.8.3, left panel) or BDC2.5 (Vb4, center panel) on gated CD41 spleen cells. The histograms show an overlay of TCR b chain expression on
CD4 T cells expressing a single TCR (open histogram) or both TCRs (shaded histogram). The dot plot shows staining for both TCRs on gated CD4 T
cells. (B) IL-2 secretion by spleen cells from F1 mice transgenic for one TCR only (j) or both TCRs (h). Spleen cells (2 3 105/well) were stimulated
with A/J dendritic cells (104/well) and C5 protein (left) or dendritic cells from BDC2.5 and islet cell extract (right). The figure shows [3H]thymidine in-
corporation by triplicate cultures of IL-2–dependent CTLL cells. Error bars were very small and are omitted from the figure for sake of clarity. 
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V
 
b
 
8.3 chain is 10-fold lower in dual TCR F1 mice com-
pared with F1 mice transgenic for the A18 TCR only.
 
T Cells from BDC2.5 
 
3
 
 A18 F1 Mice Respond to Islet
Antigen and C5.
 
As there are no clonotype-specific anti-
bodies available for the BDC2.5 or A18 TCRs, the consti-
tutive expression of both receptors cannot formally be ver-
ified by FACS™ analysis. We therefore compared T cell
responses from BDC2.5 and A18 mice as well as the F1
strain expressing both TCRs after stimulation with either
C5 protein or a preparation of islet cell membranes that
contained the as yet unidentified antigen recognized by the
BDC2.5 TCR. As shown in Fig. 1 B, T cells from dual
TCR–expressing mice can respond to both islet cell anti-
gen and C5, indicating that both transgenic TCRs on their
surfaces are functional.
 
Dual TCR–expressing F1 Mice Develop Diabetes Spontane-
ously.
 
The spontaneous incidence of diabetes in BDC2.5
mice and F1 mice with A18 was determined in a cohort of
mice left untreated for 9 mo. Whereas the parental
BDC2.5 strain had a very low incidence of spontaneous di-
abetes, the dual TCR–expressing F1 mice became diabetic
from 3–4 mo of age. The incidence of diabetes was higher
in F1 mice transgenic for both the BDC2.5 and A18 recep-
tors compared with F1 mice expressing the BDC2.5 recep-
tor alone. F1 mice transgenic for only the A18 receptor
never developed diabetes (Fig. 2).
 
Transfer of In Vitro–activated Dual TCR T Cells Causes Di-
abetes in Adoptive Hosts.
 
A standard protocol for testing
the diabetogenic potential of T cells is transfer of activated
T cells into neonatal recipients. Spleen cells from BDC2.5 
 
3
 
A18 F1 mice transgenic for either both TCRs or only the
A18 TCR were activated in vitro with H-2E–expressing
A/J dendritic cells and C5 protein and injected into F1
A18
 
1
 
 neonates 48 h later; these adoptive host mice were
transgenic for only the A18 TCR and therefore never de-
veloped spontaneous diabetes themselves. Neonatal mice
injected with C5-activated T cells from dual TCR–express-
ing mice developed fulminant diabetes within 1 wk after
transfer (Fig. 3). In contrast, injection of C5-activated F1
A18
 
1
 
 cells, which express only the C5-specific TCR, did
not result in diabetes. Similarly, the injection of C5-acti-
vated dual TCR T cells resulted in rapid onset of diabetes
upon transfer into adult F1 A18
 
1
 
 mice. These data indicate
that activation of the second—in this case C5-specific—
TCR could indeed activate the diabetogenic potential of
dual TCR–expressing T cells.
 
Immunization of Dual TCR–expressing F1 Mice Does Not
Induce Diabetes but Instead Protects against Spontaneous Onset
of Diabetes.
 
Given that C5 activation in vitro was able to
induce the diabetogenic potential of dual TCR–expressing
T cells, we proceeded to test this phenomenon in vivo. F1
dual TCR mice were immunized between 6–8 wk of age
with C5 protein or C5 peptide either in CFA or with PBS.
Control mice received CFA or PBS alone. In contrast to
the results we obtained after in vitro activation of T cells,
immunization with C5 protein or peptide did not result in
onset of diabetes. Other immunization protocols used were
subcutaneous injection with 
 
Escherichia coli
 
 expressing a C5
fusion protein with maltose binding protein, which has
previously been shown to be a powerful immunogen; scar-
Figure 2. The cumulative in-
cidence of diabetes is shown for
a cohort of F1 dual TCR mice
(transgenic for both TCR, h, 28
mice), F1 A181 mice (trans-
genic for the A18 receptor only,
n, 10 mice), F1 BDC1 (trans-
genic for the BDC2.5 receptor
only, s, 10 mice), and the pa-
rental BDC2.5 strain (m, 13 mice).
Animals were considered diabetic
after two consecutive measure-
ments  .12 mM blood glucose.
Figure 3. Blood glucose levels
in neonatal BDC2.5 3 A18 F1
mice (transgenic for the A18
TCR only) after adoptive trans-
fer of 107 T cells from C5-acti-
vated adult dual TCR–express-
ing F1 mice (j, 5 mice).
Control groups received an
equivalent number of C5-stimu-
lated T cells from F1 mice trans-
genic for the A18 TCR only (s,
4 mice) or nonactivated T cells
from dual TCR mice (h, 3
mice). Adult BDC2.5 3 A18
(transgenic only for the A18 TCR) recipients for 107 C5-activated T cells
from dual TCR–expressing mice are shown as m (5 mice). Each symbol
represents one mouse.
Figure 4. Blood glucose levels in A18 3 BDC2.5 dual TCR mice that
were either immunized with C5 protein or peptide (d) or treated with
PBS or CFA alone (s). Immunization took place at 4–6 wk of age. Each
circle represents a single mouse, and circles are spaced in four columns for
each month of age to make it easier to follow the development of indi-
vidual mice. For the last time point at 5 mo, not all mice were still avail-
able, as a proportion of mice had been killed for in vitro experiments.580 Prevention of Diabetes by Dual TCR Expression
ification of ear skin with a DNA construct encoding C5;
and intravenous injection of dendritic cells pulsed with C5
peptide. We did not observe induction of diabetes under
any of these protocols (data not shown). On the contrary, it
emerged that mice immunized with various forms of C5
antigen were protected from spontaneous onset of diabetes.
Fig. 4 summarizes data from a cohort of mice immunized
with either C5 protein or C5 peptide in CFA (mice
pooled) compared with control mice that received PBS or
CFA alone, showing blood glucose levels for both groups
at different ages. Only three mice in the immunized group
became diabetic, whereas the majority of the control mice
were diabetic by 4 mo of age.
Cells from lymph nodes draining the pancreas were ana-
lyzed for cytokine secretion after in vitro restimulation
with C5. It was evident that cells from immunized F1 dual
TCR mice produced less IL-2 and IFN-g than those of
control F1 dual TCR mice (Fig. 5). There was no differ-
ence in IL-10 production, and IL-4 secretion (data not
shown) was not detectable.
Discussion
In this paper, we tested the hypothesis that T cells ex-
pressing two TCRs might be involved in triggering the
onset of autoimmune disease. We pursued this hypothesis,
which was first proposed by Padovan et al. (3), because of
our finding that dual TCR T cells that had escaped from
thymic deletion due to low expression of the self-specific
TCR could be activated for autoreactive effector function
by triggering through the second, nonself-specific TCR
(6). There was no in vivo correlate for the autoreactivity
demonstrated in vitro, and we attributed this to the pres-
ence of systemic and high levels of self-antigen in the pe-
riphery for this model. The choice of the BDC2.5 TCR-
transgenic strain for testing the hypothesis in vivo was
prompted by the description that this diabetogenic TCR is
not subjected to negative selection in the thymus, the au-
toantigen, albeit not identified on the molecular level, is re-
stricted to pancreas islet cells, autoimmune disease has a de-
layed onset in these mice, and the introduction of H-2E
molecules is not protective as in the nontransgenic NOD
strain (8).
T cells in the periphery of genetically susceptible indi-
viduals carrying receptors specific for autoantigen expressed
in the pancreas normally should not cause any harm given
the recirculation characteristics of naive T cells, which ex-
clude their access to peripheral tissues (18). Therefore, the
crucial question is how potentially diabetogenic T cells get
activated to allow them to enter the pancreas and cause de-
struction. Several possibilities exist. For instance, dendritic
cells might carry antigens from the pancreas to draining
lymph nodes. This scenario took place in a transgenic
model in which ovalbumin, exclusively expressed by islet
cells, was cross-presented by bone marrow–derived APCs,
resulting in activation of ovalbumin-specific transgenic
CD8 T cells in lymph nodes draining the pancreas but not
in other lymphoid sites (19). Similarly, activated T cells
from BDC2.5 mice were found only in the islets and drain-
ing lymph nodes, suggesting transport of islet antigens to
this site (20). However, dendritic cells do not constitutively
engage in this form of presentation, termed cross-presenta-
tion, but appear to require the donor cell to undergo apop-
totic death (21). It is debatable, therefore, whether antigens
expressed by cells in the pancreas (unless they are secreted)
are constitutively processed by dendritic cells and trans-
ported to lymph nodes, although it may be possible that in-
dividuals genetically susceptible to diabetes have a higher
baseline rate of apoptosis in the pancreas, which might sup-
port such a mechanism.
An alternative explanation for how diabetogenic T cells
may be activated takes into account that the onset of many
autoimmune diseases is correlated with microbial infections,
proposing either molecular mimicry, i.e., cross-reactive rec-
ognition of peptides shared by pathogens and auto-antigens
(12, 22, 23) or bystander activation by inflammatory cyto-
kines released in the course of immune responses to patho-
gens (24–27). Activation of a second, e.g., pathogen-spe-
cific TCR on potentially autoreactive T cells could be
another way of involving pathogens in the induction of
disease.
The results we obtained with mice expressing a diabeto-
genic TCR from the BDC2.5 TCR-transgenic strain to-
gether with the C5-specific TCR A18 indicate that activa-
tion of dual TCR cells by stimulation with C5 in vitro and
transfer into neonatal or adult BDC2.5 3 A18 F1 mice in-
deed results in rapid development of diabetes. However,
immunization in vivo did not give the same results. On the
contrary, we observed that immunized mice were pro-
tected from the spontaneous onset of diabetes, which oc-
curs with high frequency in this strain combination. This
Figure 5. Cytokine production of
pancreatic lymph node cells from im-
munized (h) or control (j) dual TCR
mice aged 8–10 wk. Left, IL-2 produc-
tion assessed by proliferation of the
IL-2–dependent CTLL line; center,
IFN-g production and right, IL-10
production, both measured in ELISA.581 Fossati et al.
suggests that T cells within the immunized mice exerted a
regulatory influence on otherwise diabetogenic T cells
newly emerging from the thymus. Although the underly-
ing mechanisms of protection and regulation remain elu-
sive, there are a number of points worth considering.
First, the expression of the C5 TCR, as indicated by
staining with anti-Vb8.3 antibody, was drastically reduced
in dual TCR F1 mice compared with F1 mice carrying
only the A18 transgene. Because we do not have clono-
typic or Va-specific antibodies for either receptor, we can-
not formally exclude the possibility that this is due to pref-
erential pairing of the BDC Vb chain with the A18 Va
chain. However, these cells have reasonable reactivity to
C5 stimulation, indicating that they must express the cor-
rect TCR. In several other TCR combinations, many of
which were on a Rag2/2 background, the presence of a
second TCR resulted in reduction of the levels of the C5
TCR, even if there was no negative selection pressure
from the presence of C5 (6). The only exception was a dual
TCR combination with the H-Y specific, H-2Ek–restricted
A1 TCR (28) in which both receptors were expressed at
equivalent levels (our unpublished data); this combination
was also the only one in which both TCRs were expressed
in the same construct under control of the human CD2
promoter. We assume that the overall level of TCRs on T
cells is adjusted during thymic development, but it is not
clear what factors are dictating the relative TCR levels.
Positive selection in the thymus and subsequent survival
signals in the periphery may provide signals that allow high
surface expression of a TCR. It is interesting to note that
dual TCR expression by thymocytes was prominent in im-
mature subpopulations but much rarer in mature single
positive thymocytes (29); however, the latter frequently
expressed a second TCR intracellularly (30).
Irrespective of low C5 TCR expression, in vitro stimu-
lation with C5 efficiently activated dual TCR T cells from
the BDC2.5 3 A18 F1 mice. However, in vitro activation,
compared with immunization in vivo, is likely to be artifi-
cially optimized. Supplementation with highly efficient
dendritic cells as APCs as well as optimal contact in close
proximity to APC and antigen might allow strong stimula-
tion even if the expression of TCR is reduced, whereas it
may be difficult to achieve in vivo. T cells may be driven
into different response modes depending on receptor levels
and stimulus strength (31). In several experimental models
(32–34), a phenotype of apparent ‘anergy’ is coupled with
regulatory activity. Although we have no direct evidence
for such a phenomenon in our system, the finding that pro-
tection from diabetes takes place despite the presence of a
thymus that would continue to export new T cells suggests
that an active mechanism is operative.
Thus, although in principle the starting hypothesis is not
incorrect, it seems that the physiological behavior of dual
TCR T cells cannot be predicted in simple terms. Al-
though it has been argued that dual TCR–expressing T
cells are immunologically less effective than single TCR
cells (35), this does not seem to preclude functional activ-
ity. For instance, T cells expressing low levels of autoreac-
tive receptors together with unidentified additional recep-
tors were capable of initiating autoimmune responses in
vivo (36), whereas using the BDC2.5 strain on different
MHC backgrounds, Lühder et al. (37) describe a protective
effect of MHC class II molecules that exerts itself through
selection of T cells with additional TCRs. In our experi-
mental system, BDC2.5 mice crossed to A18 were not pro-
tected from diabetes by the presence of MHC alleles of the
A/J strain; in fact, the F1 combination had a far higher in-
cidence of diabetes than the parental BDC2.5 strain. In-
stead, protection was induced by in vivo stimulation of the
C5-specific TCR. It is unclear at the time of this writing
what the underlying mechanisms for protection are. IL-10
has been invoked as a ‘suppressive’ cytokine (38), but in
our study we could not detect any significant differences in
IL-10 production between cells from immunized and pro-
tected dual TCR mice, whereas there was a significant re-
duction in IL-2 and IFN-g secretion in the former group.
NOD mice can be protected from diabetes by many types
of immunostimulation, including nonspecific (e.g., CFA)
stimulation (39–41), and perturbations of the cytokine mi-
lieu have been suggested as the underlying cause for this ef-
fect. It is difficult to rule out subtle changes in the internal
cytokine milieu that are not detected in the in vitro assays,
but CFA, which protects nontransgenic NOD mice, had
no such effect in the dual TCR-transgenic mice (Fig. 4).
Although the frequency of T cells with two functionally
relevant TCRs may be low (42, 43) under physiological
conditions, it does exist (44). T cells expressing additional
TCRs are not obligatory for development of autoimmune
disease, but as our and other data show, they may contrib-
ute to it, either by exacerbating or downmodulating the
onset of autoimmune destruction (36, 37). Differential ex-
pression levels of TCR provide a way for modulation of
antigenic signals (45), and evidence is accumulating that
suboptimal signals drive cells into alternative response
modes rather than just leaving them unresponsive, so that
they may be able to regulate the degree and mode of acti-
vation of other T cells.
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